- Home
- STEC vs BNR Comparison
STEC vs BNR Comparison
Compare STEC & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STEC
- BNR
- Stock Information
- Founded
- STEC 2006
- BNR 2014
- Country
- STEC Hong Kong
- BNR China
- Employees
- STEC N/A
- BNR N/A
- Industry
- STEC
- BNR Medical Specialities
- Sector
- STEC
- BNR Health Care
- Exchange
- STEC NYSE
- BNR Nasdaq
- Market Cap
- STEC 63.8M
- BNR 38.3M
- IPO Year
- STEC 2021
- BNR 2020
- Fundamental
- Price
- STEC $0.74
- BNR $6.47
- Analyst Decision
- STEC
- BNR
- Analyst Count
- STEC 0
- BNR 0
- Target Price
- STEC N/A
- BNR N/A
- AVG Volume (30 Days)
- STEC 10.9K
- BNR 53.8K
- Earning Date
- STEC 08-05-2025
- BNR 08-21-2025
- Dividend Yield
- STEC N/A
- BNR N/A
- EPS Growth
- STEC N/A
- BNR N/A
- EPS
- STEC N/A
- BNR N/A
- Revenue
- STEC $10,672,000.00
- BNR $72,112,038.00
- Revenue This Year
- STEC $9,392.20
- BNR $136.32
- Revenue Next Year
- STEC N/A
- BNR N/A
- P/E Ratio
- STEC N/A
- BNR N/A
- Revenue Growth
- STEC N/A
- BNR 0.53
- 52 Week Low
- STEC $0.20
- BNR $2.18
- 52 Week High
- STEC $3.25
- BNR $9.48
- Technical
- Relative Strength Index (RSI)
- STEC 40.44
- BNR 60.79
- Support Level
- STEC $0.70
- BNR $5.81
- Resistance Level
- STEC $0.80
- BNR $9.48
- Average True Range (ATR)
- STEC 0.08
- BNR 0.90
- MACD
- STEC 0.00
- BNR 0.12
- Stochastic Oscillator
- STEC 38.55
- BNR 45.86
About STEC SANTECH HOLDINGS LIMITED
Santech Holdings Ltd is a technology company focusing on exploring various opportunities in consumer technology, consumer healthcare and enterprise technology. It has two revenue segments Wealth management service and Asset management service. Key revenue is generated from Wealth management service.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.